[ad_1]
FDA Advisers Recommend Pfizer ‘s (NYSE:) Paxlovid Full Approval in 16-1 Vote
- votes 16-1 (16-Yes; 1- No; 0-Abstain) in favor of PAXLOVID’s overall benefit-risk assessment when used for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
[ad_2]
Source link